Posted by Michael Wonder on 24 Dec 2022
Adaptimmune announces initiation of biologics license application submission for afami-cel, its first generation engineered TCR T-cell therapy targeting MAGE-A4, for the treatment of synovial sarcoma
23 December 2022 - Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumour.
Adaptimmune Therapeutics today reports that it has initiated the submission of a biologics license application to the US FDA seeking marketing approval for afami-cel for use as a single-dose regimen for the treatment of advanced synovial sarcoma.
